Ontario's drug plan to require switch to biosimilars
The Globe and Mail is reporting that Ontario will join several other provinces in requiring biosimilars to be used over brand-name biologics for those covered under its drug plan. Some patients will be exempt, such as those who are pregnant and have some kinds of cancer.